Vivitrol receives Priority Review

FDA accepted for filing and granted Priority Review to an sNDA from Alkermes Inc. (NASDAQ:ALKS) for Vivitrol naltrexone to treat opioid dependence. The PDUFA date is Oct. 12. The injectable sustained-...